Scancell Holdings plc (AIM: SCLP)
Health Care · Biotechnology · GB
£0.10
-0.00% today · -5.4% 1Y
Scancell Holdings plc (AIM: SCLP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $160.27M.
Over the last twelve months the share price has lost 5.4%, trading between 0.08 and 0.30.
Tweenvest scores Scancell Holdings plc across four factors: quality 19/100, value 49/100. Its strongest factor is value.
SCLP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $160.27M
- Revenue (TTM)
- $6.19M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- £0.30
- 52-week low
- £0.08
- Avg volume (3M)
- —
- Shares outstanding
- 1.21B
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.82 | +0.39% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.06 | -0.48% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.